A 27-week open-label trial to characterize the safety and tolerability of orally administered ziprasidone in children and adolescent subjects with bipolar I disorder (manic or mixed), schizophrenia or schizoaffective disorder

Trial Profile

A 27-week open-label trial to characterize the safety and tolerability of orally administered ziprasidone in children and adolescent subjects with bipolar I disorder (manic or mixed), schizophrenia or schizoaffective disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2008

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Bipolar I disorders; Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top